RxDoctor Payments Data

Dalton Dove, MD

Pulmonary Disease · Goldsboro, NCNPI 1447297809

Payments from drug & device makers

$5,492in general payments, 2019–2025

Across 306 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$477
  • Genentech USA, Inc.$410
  • GSK$333
  • Teva Pharmaceuticals USA, Inc.$314
  • Supernus Pharmaceuticals, Inc.$309
  • AstraZeneca$257
  • plus $3K from 54 others

What the payments were for

  • Food & beverage$5,476100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis29$477
Genentech USA, Inc.23$410
GSK22$333
Teva Pharmaceuticals USA, Inc.16$314
Supernus Pharmaceuticals, Inc.20$309
AstraZeneca(2 entities)14$257
AbbVie(2 entities)11$218
Boehringer Ingelheim12$199
UCB, Inc.10$194
Merck8$165
Sanofi6$163
MDD US Operations, LLC7$143
Insmed, Inc.7$123
Lilly USA, LLC8$117
SK Life Science, Inc.5$114
Neurocrine Biosciences, Inc.6$108
Biohaven Pharmaceutical Holding Company Ltd.6$107
Eisai Inc.6$100
Mallinckrodt Hospital Products Inc.5$99
Regeneron Healthcare Solutions, Inc.4$96
Mylan Specialty L.p.6$89
Amgen4$84
TG Therapeutics, Inc.3$81
Biogen3$70
Novo Nordisk4$68
Abbott3$67
Neurelis, Inc.3$63
Amneal Pharmaceuticals LLC4$62
Lundbeck LLC3$62
Advanced Respiratory, Inc3$52
Amarin Pharma, Inc.3$48
Aucta Pharmaceuticals, Inc.3$46
Baxter Healthcare2$46
Biohaven Pharmaceuticals, Inc.3$43
Avion Pharmaceuticals2$35
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$34
Verona Pharma, Inc.1$29
Pfizer2$28
Adamas Pharmaceuticals, Inc.2$28
Arbor Pharmaceuticals, Inc.2$27
BETA Bionics, Inc.1$26
Banner Life Sciences, LLC1$24
EMD Serono, Inc.1$23
Actelion Pharmaceuticals US, Inc.1$23
Exact Sciences1$21
Vertical Pharmaceuticals, LLC1$20
Recordati_rare_diseases_inc.1$20
Dexcom, Inc.1$19
Electromed, Inc.1$19
Inspire Medical Systems, Inc.1$18
Vivus LLC1$16
Philips North America LLC1$15
Acorda Therapeutics, Inc1$15
Axsome Therapeutics, Inc.1$15
Mannkind Corporation1$14
Mallinckrodt Enterprises LLC1$14
Xeris Pharmaceuticals, Inc.1$14
Astellas Pharma US Inc1$13
Johnson & Johnson1$13
Avanir Pharmaceuticals, Inc.1$12

How this compares

$5,492 in reported general payments places this provider in the 65th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$140,296
Medicare patients
466
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$63,097
Breo ElliptaFluticasone/Vilanterol36$17,658
Spiriva RespimatTiotropium Bromide33$17,096
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,361
SymbicortBudesonide/Formoterol Fumarate37$8,858
XareltoRivaroxaban12$6,571
Incruse ElliptaUmeclidinium Bromide16$6,372
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,241
Advair HfaFluticasone Propion/Salmeterol13$4,986
Fluticasone-VilanterolFluticasone/Vilanterol15$3,755
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,917
Albuterol Sulfate HfaAlbuterol Sulfate71$2,124
Ventolin HfaAlbuterol Sulfate16$1,247
Modafinil11$653
Montelukast Sodium63$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$333$98,488154 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$199$23,33746 claims
AstraZenecaSymbicort$257$8,85837 claims
Johnson & JohnsonXarelto$13$6,57112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →